ravulizumab
Asset
Monoclonal antibody that inhibits terminal complement component C5
- Stage
- Phase 3
- Modality
- Antibody
- Target
- Inflammation
- 2
- Indications
- 1
- Trial
- 1
- Developer
Indications
2IgAN
Phase 3, Active not recruiting, NCT06291376, clinicaltrials.gov, 7 Oct 2026
Immunoglobulin a nephropathy
Phase 3, Active not recruiting, NCT06291376, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors1
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026, 1 source